今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

正丹股份(300641.SZ)慷慨分红 每10股派发现金红利0.2元 股权登记日为6月20日

上海 - 2024年6月18日 - 正丹股份(300641.SZ)今日宣布公司将实施2023年度权益分派，每10股派发现金股利0.2元(含税)，股权登记日为6月20日。这意味着持有正丹股份每10股的投资者将可获得2元现金分红。

正丹股份此次分红体现了公司对股东的回报力度。2023年，尽管受全球经济复苏乏力、化工行业整体盈利不佳等因素影响，正丹股份仍实现归属于母公司所有者的净利润987.51万元，公司经营平稳，主营业务、核心竞争力等未发生重大变化。

正丹股份是一家专业从事精细化学品研发、生产、销售的国家高新技术企业，公司主要产品为染料中间体、医药中间体、农药中间体等。公司产品广泛应用于纺织印染、医药、农药等领域，客户遍布全球。

近年来，正丹股份坚持创新驱动发展战略，不断加大研发投入，提升产品科技含量，增强市场竞争力。公司先后开发出多个具有高附加值、高技术含量的拳头产品，在市场上享有较高的知名度和美誉度。

正丹股份表示，公司将继续坚持以市场为导向，以科技创新为动力，不断提升产品质量和服务水平，努力为股东创造更大价值。

以下是本次分红的一些重要信息：

• 分红派息方式：现金分红
• 每股分红：0.2元 (含税)
• 股权登记日：2024年6月20日
• 红利发放日：待公司另行公告

正丹股份此次分红派息彰显了公司对股东的回报力度，也体现了公司良好的经营状况和发展前景。相信在公司管理层的带领下，正丹股份将继续稳健发展，为股东创造更大的价值。